Close Menu

financial guidance

Danaher Q2 net earnings fell 5 percent to $656.7 million, or $.94 per diluted share, from $695.7 million, or $.97 per diluted share, a year ago.

Luminex's anticipated FY 2016 revenue growth of 6 percent to 9 percent could potentially push higher into the double digits following the integration of Nanosphere.

After selling Focus Diagnostics' products business to DiaSorin for $300 million, Quest now estimates annual revenues of between $7.47 billion and $7.54 billion.

The company said it placed two ICell8 Single-Cell Systems during the quarter, doubling the number of systems placed since the product's launch last October.

The firm missed analyst estimates for revenues and loss per share, citing a continued investment in its AlloSure NGS test for the wider-than-expected loss.

The company said it completed about 40,000 Cologuard tests in Q1, and that the cumulative number of physicians ordering the test since its launch has risen to 32,000.

The company reported record assay and royalty revenues, and said that system revenues grew 39 percent year over year.

The scientific products giant reported revenue of $4.29 billion during the quarter, which ended on April 2 this year, compared to March 28 last year.

The life science and diagnostics company's revenues were short of analyst expectations, though its earnings per share were in line with estimates.

The company beat analyst estimates for both revenues and earnings per share during the quarter, due largely to double-digit growth in its US business.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.